SCHEMBL3918592

SCHEMBL3918592

O=C(C1CCN(S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(CC2)C1

nearest known ligand 0.73

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.73
HTT P42858 1/20 0.70
POLB P06746 1/20 0.64
ALDH1A1 P00352 4/20 0.58
LMNA P02545 3/20 0.58
USP2 O75604 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
RAB9A P51151 2/20 0.58
KMT2A Q03164 2/20 0.58
GAA P10253 1/20 0.58
LSS P48449 1/20 0.58
MEN1 O00255 1/20 0.55
HPGD P15428 1/20 0.55
TSHR P16473 1/20 0.55
EPHX2 P34913 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2285784 0.81 ALDH1A1 (0.76) NPC1HTTPOLBALDH1A1LMNA
SCHEMBL14825104 0.79 GAA (0.78) NPC1HTTPOLBALDH1A1LMNA
SCHEMBL3923242 0.79 HPGD (0.76) NPC1HTTPOLBALDH1A1LMNA
SCHEMBL3929775 0.78 NPC1 (0.58) NPC1HTTPOLBALDH1A1LMNA
SCHEMBL20240865 0.78 ALDH1A1 (0.72) NPC1HTTALDH1A1LMNASMN1; SMN2
Zinc Ion SCHEMBL9443922 0.77 NPC1 (0.63) NPC1HTTALDH1A1LMNAUSP2
SCHEMBL7435515 0.75 NPC1 (0.70) NPC1HTTALDH1A1LMNASMN1; SMN2
SCHEMBL3917592 0.75 NPC1 (0.64) NPC1HTTPOLBALDH1A1LMNA
SCHEMBL5472868 0.74 ALDH1A1 (0.69) NPC1HTTALDH1A1LMNAUSP2
SCHEMBL10154252 0.74 ALDH1A1 (0.69) NPC1ALDH1A1SMN1; SMN2RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-12-10 US claimed
EP-2038255-A2 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES High Point Pharmaceuticals, LLC (US) 2009-03-25 EP claimed
WO-2007144394-A2 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC. (US) 2007-12-21 WO claimed
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-12-10 US disclosed
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-12-10 US disclosed
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-12-10 US disclosed
EP-2038255-A2 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES High Point Pharmaceuticals, LLC (US) 2009-03-25 EP disclosed
WO-2007144394-A2 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC. (US) 2007-12-21 WO disclosed
WO-2007144394-A2 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HSD11B1, HSD3B1, CES1 NPC1 531/4885HTT 3305/4885POLB 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.